MedTrace Logo

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

NCT06907095 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5909

Last updated 2026-03-30

No results posted yet for this study

Summary

LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease.

The main objective of LEAH is to evaluate and compare the sensitivity of different tests on body fluids to detect cancers that will occur within 3 years of inclusion in the study, in a cohort of individuals identified as being at increased risk of cancer.

Conditions

  • Risk of Breast Cancer
  • Risk of Gynaecological Cancer
  • Risk of Colorectal Cancer
  • Risk of Upper Gastrointestinal Cancers
  • Risk of Hepatic Cancers
  • Risk of Lung Cancer
  • Risk of Skin Cancers Except Basal-cell Carcinomas
  • Risk of Head and Neck Cancers
  • Risk of Mesothelioma
  • Risk of Kidney Cancer
  • Risk of Prostate Cancer
  • Risk of Urothelial Cancers
  • Risk of Endocrine Cancers
  • Risk of Hematologic Malignancies
  • Risk of Several Cancer Types
  • Risk of Second Malignancy in Individuals Treated for a Childhood Cancer
  • Risk of Neoplasia

Interventions

DIAGNOSTIC_TEST

biological samples

biological samples (blood, urine, saliva)

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Suzette Delaloge, MD · Gustave Roussy, Veillejuif, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-16
Primary Completion
2030-06-30
Completion
2030-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06907095 on ClinicalTrials.gov